OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Sanjay Popat, Christian Grohé, J. Corral, et al.
Lung Cancer (2020) Vol. 144, pp. 76-84
Open Access | Times Cited: 36
Sanjay Popat, Christian Grohé, J. Corral, et al.
Lung Cancer (2020) Vol. 144, pp. 76-84
Open Access | Times Cited: 36
Showing 1-25 of 36 citing articles:
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 365
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 365
Eubacterium rectale Improves the Efficacy of Anti-PD1 Immunotherapy in Melanoma via l -Serine-Mediated NK Cell Activation
Nian Liu, Lihui Chen, Mingjie Yan, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 26
Nian Liu, Lihui Chen, Mingjie Yan, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 26
Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
Xuan Wang, Xiaowen Wu, Yue Yang, et al.
European Journal of Cancer (2023) Vol. 182, pp. 57-65
Closed Access | Times Cited: 18
Xuan Wang, Xiaowen Wu, Yue Yang, et al.
European Journal of Cancer (2023) Vol. 182, pp. 57-65
Closed Access | Times Cited: 18
An Overview of Cancer Biology, Pathophysiological Development and It’s Treatment Modalities: Current Challenges of Cancer anti-Angiogenic Therapy
Fares Hezam Al-Ostoot, Salma Salah, Shaukath Ara Khanum
Cancer Investigation (2024) Vol. 42, Iss. 7, pp. 559-604
Closed Access | Times Cited: 7
Fares Hezam Al-Ostoot, Salma Salah, Shaukath Ara Khanum
Cancer Investigation (2024) Vol. 42, Iss. 7, pp. 559-604
Closed Access | Times Cited: 7
The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2)
Valeria da Costa, Sandra J. van Vliet, Paula Carasi, et al.
Cancer Letters (2021) Vol. 518, pp. 72-81
Closed Access | Times Cited: 34
Valeria da Costa, Sandra J. van Vliet, Paula Carasi, et al.
Cancer Letters (2021) Vol. 518, pp. 72-81
Closed Access | Times Cited: 34
Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade
Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112162-112162
Open Access | Times Cited: 15
Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112162-112162
Open Access | Times Cited: 15
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives
Martin Reck, Sanjay Popat, Christian Grohé, et al.
Lung Cancer (2023) Vol. 179, pp. 107173-107173
Closed Access | Times Cited: 15
Martin Reck, Sanjay Popat, Christian Grohé, et al.
Lung Cancer (2023) Vol. 179, pp. 107173-107173
Closed Access | Times Cited: 15
Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
Charlotte Lovatt, Alan L. Parker
Cancers (2023) Vol. 15, Iss. 16, pp. 4178-4178
Open Access | Times Cited: 14
Charlotte Lovatt, Alan L. Parker
Cancers (2023) Vol. 15, Iss. 16, pp. 4178-4178
Open Access | Times Cited: 14
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
Yunlong Jia, Lihua Liu, Baoen Shan
Annals of Translational Medicine (2020) Vol. 8, Iss. 17, pp. 1095-1095
Open Access | Times Cited: 34
Yunlong Jia, Lihua Liu, Baoen Shan
Annals of Translational Medicine (2020) Vol. 8, Iss. 17, pp. 1095-1095
Open Access | Times Cited: 34
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials
Xingxiang Pu, Jiawei Shou, Zemin Xiao, et al.
Advances in Therapy (2025)
Closed Access
Xingxiang Pu, Jiawei Shou, Zemin Xiao, et al.
Advances in Therapy (2025)
Closed Access
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Zahraa Rahal, Roy El Darzi, Seyed Javad Moghaddam, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Zahraa Rahal, Roy El Darzi, Seyed Javad Moghaddam, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?
Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 169, pp. 103538-103538
Open Access | Times Cited: 22
Amelia Insa, Paloma Martín-Martorell, Raimondo Di Liello, et al.
Critical Reviews in Oncology/Hematology (2021) Vol. 169, pp. 103538-103538
Open Access | Times Cited: 22
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
Christian Grohé, Thomas Wehler, Tobias Dechow, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 10, pp. 2010-2021
Open Access | Times Cited: 16
Christian Grohé, Thomas Wehler, Tobias Dechow, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 10, pp. 2010-2021
Open Access | Times Cited: 16
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer
Christine Auberle, Feng Gao, Mark Sloan, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 6, pp. 3782-3793
Open Access | Times Cited: 3
Christine Auberle, Feng Gao, Mark Sloan, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 6, pp. 3782-3793
Open Access | Times Cited: 3
Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
Likui Fang, Wuchen Zhao, Bo Ye, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 18
Likui Fang, Wuchen Zhao, Bo Ye, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 18
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
Martin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Lung Cancer (2020) Vol. 148, pp. 159-165
Open Access | Times Cited: 19
Martin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Lung Cancer (2020) Vol. 148, pp. 159-165
Open Access | Times Cited: 19
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study
Christian Grohé, Werner J. Blau, Wolfgang Gleiber, et al.
Clinical Oncology (2022) Vol. 34, Iss. 7, pp. 459-468
Open Access | Times Cited: 12
Christian Grohé, Werner J. Blau, Wolfgang Gleiber, et al.
Clinical Oncology (2022) Vol. 34, Iss. 7, pp. 459-468
Open Access | Times Cited: 12
Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
Charlotte Lovatt, Alan L. Parker
(2023)
Open Access | Times Cited: 7
Charlotte Lovatt, Alan L. Parker
(2023)
Open Access | Times Cited: 7
Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I/II study
Meiqi Shi, Ping Chen, Bin Cui, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Meiqi Shi, Ping Chen, Bin Cui, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
Phase Ib study of anlotinib in combination with anti‐PD‐L1 antibody (TQB2450 ) in patients with advanced acral melanoma
Yu Du, Jie Dai, Lili Mao, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 93-101
Closed Access | Times Cited: 6
Yu Du, Jie Dai, Lili Mao, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 93-101
Closed Access | Times Cited: 6
Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study
Junlin Yao, Zhengyang Wang, Sheng Jin, et al.
International Immunopharmacology (2020) Vol. 89, pp. 107033-107033
Closed Access | Times Cited: 16
Junlin Yao, Zhengyang Wang, Sheng Jin, et al.
International Immunopharmacology (2020) Vol. 89, pp. 107033-107033
Closed Access | Times Cited: 16
Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma
Bixia Tang, Jiazhi Mo, Xieqiao Yan, et al.
European Journal of Cancer (2021) Vol. 156, pp. 83-92
Closed Access | Times Cited: 14
Bixia Tang, Jiazhi Mo, Xieqiao Yan, et al.
European Journal of Cancer (2021) Vol. 156, pp. 83-92
Closed Access | Times Cited: 14
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Akio Tada, Toshiyuki Minami, Hidemi Kitai, et al.
Lung Cancer (2023) Vol. 180, pp. 107219-107219
Open Access | Times Cited: 4
Akio Tada, Toshiyuki Minami, Hidemi Kitai, et al.
Lung Cancer (2023) Vol. 180, pp. 107219-107219
Open Access | Times Cited: 4
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Marco Siringo, Javier Baena, Helena Bote de Cabo, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5505-5505
Open Access | Times Cited: 4
Marco Siringo, Javier Baena, Helena Bote de Cabo, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5505-5505
Open Access | Times Cited: 4
